Oncotarget
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases.The term was introduced in the inaugural Editorial,Introducing Oncotarget.
As of January 1, 2022,Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
SSP 47th Annual Meeting
Post-Publication Promotion
Learn about ourFREE
Impact Journals, LLC is the publisher of Oncotarget:www.impactjournals.com.
Impact Journals is a member of theWellcome Trust List of Compliant Publishers.
Impact Journals is a member of theSociety for Scholarly Publishing.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.This malicious action will be reported to the FBI.
Current Volume
This Month's Popular DOIs
(Crossref resolutions)
| 10.18632/ONCOTARGET.6429 |
| 10.18632/ONCOTARGET.5435 |
| 10.18632/ONCOTARGET.19087 |
| 10.18632/ONCOTARGET.9859 |
| 10.18632/ONCOTARGET.23208 |
Most popular Oncotarget DOIs, measured by the number of times each DOI was successfully resolved.
Most Popular DOIs Published in 2024
(Crossref Data)
Most Popular DOIs of 2024
(Crossref Data)
Milestones in Modern Scholarly Publishing
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025.Learn more here.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds.Learn more.
Oncotarget.org: Blog Posts on
New & Trending Papers
Oncotarget.net: Latest Insights
From Our Authors
June 4, 2019
About The Cover
The cover for issue 38 of Oncotarget features Figure 6, "A model summarizing the role of RNA modification genes in melanoma growth and development," byMalvi, et al.
Table of Contents
Editorial
| Cyr61/CCN1 targets for chemosensitization in pancreatic cancer |
https://doi.org/10.18632/oncotarget.26986 Snigdha Banerjee,Arnab Ghosh,Daniel D. VonHoff, and Sushanta K. Banerjee |
| 3579-3580 |
| PDF | How to cite |
Priority Research Papers
| Elevated telomere dysfunction in cells containing the African-centric Pro47Ser cancer-risk variant of TP53 |
https://doi.org/10.18632/oncotarget.26980 Stephen Tutton,Zhong Deng,Nitish Gulve,Olga Vladimirova,Kate Beishline,Andreas Wiedmer,Maureen Murphy, and Paul M. Lieberman |
| 3581-3591 |
| Abstract | PDF | Full Text | How to cite |
Research Papers
| Flow based single cell analysis of the immune landscape distinguishes Barrett’s esophagus from adjacent normal tissue |
https://doi.org/10.18632/oncotarget.26911 Moen Sen,Friedrich Hahn,Taylor A. Black,Maureen DeMarshall,Warren Porter,Eileen Snowden,Stephanie S. Yee,Frances Tong,Mitchell Ferguson,Emylee N. Fleshman,Hiroshi Nakagawa,Gary W. Falk,Gregory G. Ginsberg,Michael L. Kochman,Rainer Blaesius,Anil K. Rustgi, and Erica L. Carpenter |
| 3592-3604 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite |
| Prognostic significance of the pretreatment prognostic nutritional index in patients with epithelial ovarian cancer |
https://doi.org/10.18632/oncotarget.26914 Naoko Komura,Seiji Mabuchi,Eriko Yokoi,Kotaro Shimura,Mahiru Kawano,Yuri Matsumoto, and Tadashi Kimura |
| 3605-3613 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite |
| Molecular characterization of carcinosarcomas arising in the uterus and ovaries |
https://doi.org/10.18632/oncotarget.26942 Marta Brunetti,Antonio Agostini,Julie Staurseth,Ben Davidson,Sverre Heim, and Francesca Micci |
| 3614-3624 |
| Abstract | PDF | Full Text | How to cite |
| A three-step approach identifies novel shear stress-sensitive endothelial microRNAs involved in vasculoprotective effects of high-intensity interval training (HIIT) |
https://doi.org/10.18632/oncotarget.26944 Boris Schmitz,Franziska L. Breulmann,Bothaynah Jubran,Florian Rolfes,Lothar Thorwesten,Michael Krüger,Andreas Klose,Hans-Joachim Schnittler, and Stefan-Martin Brand |
| 3625-3640 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite |
| Deep sequencing of a recurrent oligodendroglioma and the derived xenografts reveals new insights into the evolution of human oligodendroglioma and candidate driver genes |
https://doi.org/10.18632/oncotarget.26950 Nadin D. Exner,Jaime Alberto Campos Valenzuela,Khalil Abou-El-Ardat,Hrvoje Miletic,Peter C. Huszthy,Petra M. Radehaus,Evelin Schröck,Rolf Bjerkvig,Lars Kaderali,Barbara Klink, and Janice M. Nigro |
| 3641-3653 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite |
| Development, validation, and comparison of gene analysis methods for detectingEGFR mutation from non-small cell lung cancer patients-derived circulating free DNA |
https://doi.org/10.18632/oncotarget.26951 Masaki Hanibuchi,Akira Kanoh,Takuya Kuramoto,Tatsuro Saito,Makoto Tobiume,Atsuro Saijo,Hiroyuki Kozai,Mayo Kondo,Shun Morizumi,Hiroto Yoneda,Kozo Kagawa,Hirokazu Ogino,Seidai Sato,Hiroshi Kawano,Kenji Otsuka,Yuko Toyoda,Hiroshi Nokihara,Hisatsugu Goto, and Yasuhiko Nishioka |
| 3654-3666 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite |
| PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer |
https://doi.org/10.18632/oncotarget.26960 Sandeep Rajput,Zhanfang Guo,Shunqiang Li, and Cynthia X. Ma |
| 3667-3680 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite |
| Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential |
https://doi.org/10.18632/oncotarget.26978 Balraj Singh,Vanessa N. Sarli,Hannah E. Kinne,Anna Shamsnia, and Anthony Lucci |
| 3681-3693 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite |
| Cancer-testis antigens MAGEA proteins are incorporated into extracellular vesicles released by cells |
https://doi.org/10.18632/oncotarget.26979 Anneli Kuldkepp,Magda Karakai,Eve Toomsoo,Olavi Reinsalu, and Reet Kurg |
| 3694-3708 |
| Abstract | PDF | Full Text | How to cite |
| Functional interplay between YY1 and CARM1 promotes oral carcinogenesis |
https://doi.org/10.18632/oncotarget.26984 Amit K. Behera,Manoj Kumar,Muthu K. Shanmugam,Aditya Bhattacharya,Vinay J. Rao,Akshay Bhat,Madavan Vasudevan,Kodaganur S. Gopinath,Azeem Mohiyuddin,Anupam Chatterjee,Gautam Sethi, and Tapas K. Kundu |
| 3709-3724 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite |
| 1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours |
https://doi.org/10.18632/oncotarget.26966 Clare T. Butler,Susan A. Kennedy,Amy Buckley,Ronan Doyle,Emer Conroy,William M. Gallagher,Jacintha O’Sullivan, and Breandán N. Kennedy |
| 3725-3744 |
| Abstract | PDF | Full Text | How to cite |
| Dissecting the role of RNA modification regulatory proteins in melanoma |
https://doi.org/10.18632/oncotarget.26959 Parmanand Malvi,Biao Wang,Shreni Shah, and Romi Gupta |
| 3745-3759 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite | Podcast |  |
| Comparing progression molecular mechanisms between lung adenocarcinoma and lung squamous cell carcinoma based on genetic and epigenetic networks: big data mining and genome-wide systems identification |
https://doi.org/10.18632/oncotarget.26940 Shan-Ju Yeh,Chien-An Chang,Cheng-Wei Li,Lily Hui-Ching Wang, and Bor-Sen Chen |
| 3760-3806 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite |
| Association study of apelin-APJ system genetic polymorphisms with incident metabolic syndrome in a Chinese population: a case-control study |
https://doi.org/10.18632/oncotarget.24111 Meijin Zhang,Feng Peng,Liming Lin,Mingzhong Yu,Chengyuan Huang,Dan Hu,Qinghui Guo,Changsheng Xu, and Jinxiu Lin |
| 3807-3817 |
| Abstract | PDF | Full Text | Supplementary Information | How to cite |
Case Reports
| Regression ofBRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases |
https://doi.org/10.18632/oncotarget.26932 Peter Y.M. Woo,Tai-Chung Lam,Jenny K.S. Pu,Lai-Fung Li,Roland C.Y. Leung,Jason M.K. Ho,James T.F. Zhung,Belinda Wong,Timonthy S.K. Chan,Herbert H.F. Loong, and Ho-Keung Ng |
| 3818-3826 |
| Abstract | PDF | Full Text | How to cite |
Corrections
| Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL |
https://doi.org/10.18632/oncotarget.27011 John C. Byrd,Stephen Smith,Nina Wagner-Johnston,Jeff Sharman,Andy I. Chen,Ranjana Advani,Bradley Augustson,Paula Marlton,S. Renee Commerford,Kwame Okrah,Lichuan Liu,Elaine Murray,Elicia Penuel,Ashley F. Ward, and Ian W. Flinn |
| 3827-3830 |
| Correction | PDF | How to cite |
Copyright © 2025 Rapamycin Press LLC dba Impact Journals